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Primary coenzyme Q10 (CoQ10) deficiencies are rare, clinically heterogeneous disorders caused by mutations in several genes encoding
proteins involved in CoQ10 biosynthesis. CoQ10 is an essential component of the electron transport chain (ETC), where it shuttles elec-
trons from complex I or II to complex III. By whole-exome sequencing, we identified five individuals carrying biallelic mutations
in COQ4. The precise function of human COQ4 is not known, but it seems to play a structural role in stabilizing a multiheteromeric
complex that contains most of the CoQ10 biosynthetic enzymes. The clinical phenotypes of the five subjects varied widely, but four
had a prenatal or perinatal onset with early fatal outcome. Two unrelated individuals presented with severe hypotonia, bradycardia,
respiratory insufficiency, and heart failure; two sisters showed antenatal cerebellar hypoplasia, neonatal respiratory-distress syndrome,
and epileptic encephalopathy. The fifth subject had an early-onset but slowly progressive clinical course dominated by neurological dete-
rioration with hardly any involvement of other organs. All available specimens from affected subjects showed reduced amounts of
CoQ10 and often displayed a decrease in CoQ10-dependent ETC complex activities. The pathogenic role of all identified mutations
was experimentally validated in a recombinant yeast model; oxidative growth, strongly impaired in strains lacking COQ4, was corrected
by expression of human wild-type COQ4 cDNA but failed to be corrected by expression of COQ4 cDNAs with any of the mutations iden-
tified in affected subjects. COQ4mutations are responsible for early-onset mitochondrial diseases with heterogeneous clinical presenta-
tions and associated with CoQ10 deficiency.Coenzyme Q (CoQ), or ubiquinone, is a lipophilic com-
ponent of the electron transport chain (ETC), where it
shuttles electrons derived from NADH and FADH2 to ETC
complex III (cIII) or ubiquinone-cytochrome c reductase.
The main electron donors to CoQ are ETC complexes I
(cI) and II (cII) but also include other mitochondrial flavo-
proteins, for instance, electron transfer flavoprotein-ubi-
quinone oxidoreductase, mitochondrial (ETF-dehydroge-
nase [ETFDH]), which is the terminal component of fatty
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The Americtion pathways. CoQ can also act as an antioxidant and a
membrane stabilizer, is a cofactor of additional mitochon-
drial enzymes (e.g., uncoupling protein UCP1),1,2 and
plays an indispensable role in the de novo pyrimidine
biosynthesis as the electron acceptor from dihydroorotate
dehydrogenase.3–5
CoQ is a 1,4-benzoquinone with a tail of 10 isoprenyl
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Figure 1. Pedigrees of Investigated Families and COQ4 Structure and Conservation of Identified Mutations
(A) Pedigrees of four families affected bymutations in COQ4. Themutation status of affected and unaffected familymembers is indicated
by closed and open symbols, respectively.
(B) COQ4 structure showing the identifiedmutations. The structure of the gene product, COQ4, is also shown with known domains and
localization and conservation of amino acid residues affected by the mutations. Intronic regions are not drawn to scale.2-C-methyl-D-erythritol 4-phosphate pathways, whereas
the aromatic precursor of the CoQ benzoquinone ring is
p-hydroxybenzoate, derived from tyrosine.6 After the iso-
prenoid ‘‘tail’’ is bound to the aromatic ‘‘head,’’ the ring
undergoes sequential modification. At least ten enzymes
participate in CoQ biosynthesis; in yeast, and possibly
mammals as well, these enzymes are all localized in
mitochondria.
Primary CoQ10 deficiency is the biochemical signature
of a group of rare, clinically heterogeneous autosomal-
recessive disorders caused by mutations in several genes
encoding proteins involved in CoQ10 biosynthesis.
7 Muta-
tions in COQ2 (MIM 609825), COQ6 (MIM 614647),
ADCK3 (COQ8 [MIM 606980]), ADCK4 (MIM 615573),
COQ9 (MIM 612837), PDSS1 (MIM 607429), and PDSS2
(MIM 610564) have been reported in subjects with severe
infantile mitochondrial syndromes associated with severe
tissue CoQ10 deficiency, whereas the genetic bases under-
pinning adult-onset CoQ10 deficiency remain mostly un-
defined.8,9 COQ4 (MIM 612898) codes for a ubiquitously
expressed 265-amino-acid protein that is peripherally asso-
ciated with themitochondrial inner membrane on thema-
trix side;10 the precise function of human COQ4 is not
known, but the yeast ortholog seems to play a structural310 The American Journal of Human Genetics 96, 309–317, Februaryrole crucial in the stabilization of a multiheteromeric com-
plex including several, if not all, of the CoQ biosynthetic
enzymes.11
We report here the identification of pathogenic biallelic
COQ4 mutations in a total of five individuals from four
families; these subjects were part of a cohort of severemito-
chondrial cases where the CoQ10 defect was not antici-
pated. The family pedigrees are shown in Figure 1A.
Subject 1 (S1; II-3, family 1), a boy, was the third of four
siblings and was born to healthy, non-consanguineous
Italian parents after an uncomplicated pregnancy and
elective cesarean delivery. His oldest sister (II-1), who pre-
sented with bradycardia and hypotonia, died at birth,
and his 16-year-old second sister and his 5-year-old brother
are alive and well. At birth, S1 had a weight of 3,410 g, a
length of 49.5 cm, and a head circumference of 34.5 cm.
Apgar scores were 7 and 10 at 1 and 5 min after birth,
respectively. At birth, his condition appeared critical, given
that he showed severe hypotonia, areflexia, acrocyanosis,
bradycardia, and respiratory insufficiency. Ultrasound ex-
amination revealed markedly decreased motility of the
left ventricle with an ejection fraction of 20%–25%. No
evidence of hepatic or renal impairment was observed. Do-
butamine infusion via an umbilical venous catheter was5, 2015
Table 1. Mitochondrial ETC Activities in Muscle
Subject cI/CSa cIþIII/CSa cII/CSa cIIþIII/CSa cIII/CSa cIV/CSa CSb
Muscle biopsy S1c 36 24 N 34 N N 64
S2c 6 ND 42 43 10 30 57
S3 N N N 55 N 50 54
S4 145 N N N 222 189 109
S5 <5 ND N 30 50 N 65
Abbreviations are as follows: N, value in the control range; ND, not done; cI, complex I; cII, complex II; cIII, complex III; cIV, complex IV; cIþIII, coupled activity of
complexes I and III; and cIIþIII, coupled activity of complexes II and III. The analyses were performed in different laboratories, and the reference values are diverse
(they usually range between 60% and 140% of the mean control value). The values of ETC complex activities out of the control range (specific to each enzymatic
activity and to each laboratory) are reported.
aMean control value (%) of CS-normalized ETC complex activities.
bPercentage of mean control value.
cSample from autopsy.ineffective, and the baby died 4 hr after birth. His blood
glucose level was normal, as were renal and hepatic param-
eters; plasma creatine kinase was moderately elevated
(861 U/l; normal value [n.v.] < 400), and blood lactate
was extremely high (20.1 mM; n.v. < 2). Analysis of uri-
nary organic acids showed elevated levels of 2-OH glutaric
acid, whereas plasma and urinary amino acids were within
normal ranges. The autopsy examination revealed left ven-
tricular hypoplasia with septum hypertrophy and a patent
ductus arteriosus. No brain examination was performed.
The activities of the ETC complexes in autoptic skeletal-
muscle homogenate showed severe defects of both coupled
cIþcIII and cIIþcIII reactions, normalized to citrate syn-
thase (CS), and a decrease in CS-normalized cI (Table 1).
In both liver and cultured fibroblasts, the CS-normalized
activities of each of the individual ETC complexes were
in the control range. Although the coupled cIþcIII activity
cannot be reliably assayed in cultured cells,12 the coupled
cIIþcIII activity was clearly decreased in S1 fibroblasts
(65% of the control mean).
S2 (II-1, family 2) was born at the 34th week of gestation
and was the female first child of non-consanguineous
Japanese parents. Her birth weight was 1,120 g (2.2 SDs).
Apgar scores were 7 and 8 at 1 and 5 minutes after birth,
respectively. There was no family history of neurological
or cardiac disease. The pregnancywas complicated by severe
intrauterine growth delay and ultrasound-documented hy-
pertrophic cardiomyopathy. On S2’s first day of life, she
became apnoeic and was intubated as a result of respiratory
failure. She initially displayed moderate lactic acidosis,
but soon after her admission to Neonatal Medical Center,
her lactic acidosis rapidly worsened (blood lactate ¼ 11.2–
18.8 mM; n.v. < 2); her hypertrophic cardiomyopathy
evolved into severe heart failure, leading to death at the
age of 1 day.
Themetabolic profile (urinary and plasmatic amino acids,
organic acids, and acylcarnitines) showed no significant
findings. A liver autoptic specimen showed a severe defi-
ciency of cI (cI/CS ratio ¼ 2.9%); autoptic skeletal-muscle
homogenate also showed a cI deficiency together with less
pronounced reductions of other ETC complexes (Table 1).The AmericSisters S3 (II-1, family 3) and S4 (II-3, family 3) are the
first and third, respectively, of three siblings and were
born to healthy, non-consanguineous Austrian parents.
Their brother (II-2) is a healthy, unaffected boy. S3 and
S4 were born prematurely at gestational ages of 32 weeks
(birth weight ¼ 1,550 g) and 34 weeks (birth weight ¼
2,170 g), respectively.
Performed at the 20th week of gestation, prenatal organ
screening of S3 revealed a suspected malformation of the
cerebellum. A postnatal cranial ultrasound showed cere-
bellar hypoplasia. After birth, she showed distal arthrogry-
posis, but no other dysmorphic features. At birth, she suf-
fered from respiratory-distress syndrome, and a few hours
later, a severe myoclonic epileptic encephalopathy ensued;
blood lactic acid at 36 hr of age was 6.4 mM and rose to
14 mM prior to her death by multiorgan failure on the
third day of life. Echocardiography showed a normal heart.
Metabolic investigations (amino acids in plasma, acyl-
carnitine profile, and standard newborn screening) were
essentially normal. Analysis of organic acids in urine
showed excretion of glycerol and 2-OH-glutarate. In frozen
postmortem muscle (obtained within 30 min after death),
ETC enzyme activities were slightly decreased (Table 1). An
autopsy of the brain revealed severe olivopontocerebellar
and thalamic hypoplasia and scattered cavitations in the
white matter; the visceral organs appeared normal for the
gestational age.
Six years later, prenatal organ screening of the sister, S4,
showed cerebellar hypoplasia, suggesting the same disease
as in S3. Similar to her sister, S4 suffered from neonatal res-
piratory distress. No dysmorphic features were present.
Echocardiography was normal. A cranial ultrasound con-
firmed cerebellar hypoplasia. Six hours after birth, epileptic
encephalopathy ensued; blood lactic acid was 3.5 mM at
2 hr of age and rose to 9 mM at death on the second
day of life. Metabolic investigations showed normal
newborn-screening results and a normal acylcarnitine pro-
file. Amino acids in plasma were grossly elevated but
showed no specific pattern. Analysis of urinary organic
acids showed excretion of a ‘‘mitochondrial dysfunctional
pattern’’ with malate, fumarate, and 2-OH-glutarate, asan Journal of Human Genetics 96, 309–317, February 5, 2015 311
well as vitamin B6metabolites andN-acetyl-tyrosine. Anal-
ysis of frozen postmortem muscle showed elevated levels
of ETC activities (Table 1). In both girls, blood glucose con-
centration and renal and hepatic parameters were in the
normal range.
S5 (II-1, family 4) is an 18-year-old youngman and is the
only offspring of healthy Italian parents who deny consan-
guinity and originate from a medium-size town in south-
ern Italy. Pregnancy was normal, and delivery was via ce-
sarean section because of a podalic presentation. He was
born at term, and his weight at birth was 4,100 g. Weight
andmotor development were reportedly normal in his first
year of life, but he started to show slowly progressivemotor
deterioration after the age of 10 months, when he mani-
fested unsteadiness in maintaining acquired sitting posi-
tion. He achieved the ability to walk with a spastic ataxic
gait at 3 years of age but lost ambulation by 6 years of
age and has been wheelchair bound since then. At 12 years
of age, he started manifesting epileptic seizures in the form
of prolonged right-side hemiclonic seizures. MRI showed
bilateral increased signal intensity in fluid-attenuated-
inversion-recovery and T2-weighted sequences in both oc-
cipital-cortical and juxtacortical areas (Figures S1A–S1D).
Around the same period, he started to have swallowing dif-
ficulties. He was admitted for extensive investigation.
Thorough blood tests excluded liver and kidney involve-
ment and did not show lactic acidosis. A specific pattern
of organic aciduria was excluded. Electrophysiological ex-
amination showed a sensory motor polyneuropathy with
slowed conduction velocities. During a 5-year follow-up,
he showed a slowly progressive downhill course with
recurrent treatment-resistant seizures, worsened swallow-
ing impairment, progressive scoliosis, and cognitive deteri-
oration. A muscle biopsy was performed when he was
12 years old. Spectrophotometric assays of the ETC com-
plexes in muscle homogenate showed virtually undetect-
able cI/CS ratios and reduced cIIþcIII/CS and cIII/CS ratios.
The other ETC complex activities were within control
limits (Table 1). Since the age of 15 years, he has used a
percutaneous-endoscopic-gastronomy tube and has devel-
oped severe scoliosis with a Cobb angle of 75. Control
MRI performed when he was 17 years old showed cere-
bellar atrophy, widening of ventricular brain spaces, and
scars from cortical necrotic lesions in both occipital areas
(Figures S1E–S1H).
In agreement with the Declaration of Helsinki, informed
consent for genetic and biochemical studies was signed by
the parents of all subjects, and the ethics committee of the
Technische Universita¨t Mu¨nchen approved the study.
We performed whole-exome sequencing (WES) to inves-
tigate the molecular bases of the mitochondrial disease
presentations of S1, S4, and S5, as described previously.13
Coding DNA sequences were enriched with a SureSelect
Human All Exon 50 Mb V4 or V5 Kit (Agilent) and subse-
quently sequenced on a HiSeq2500 system (Illumina).
Read alignment to the human reference assembly (UCSC
Genome Browser hg19) was done with the Burrows-312 The American Journal of Human Genetics 96, 309–317, FebruaryWheeler Aligner (version 0.7.5), and single-nucleotide var-
iants and small insertions and deletions were identified
with SAMtools (version 0.1.19). On the basis of the rare dis-
ease phenotype and a pattern concordant with autosomal-
recessive inheritance, we sought genes carrying rare (minor
allele frequency [MAF] < 0.1% in 4,500 control exomes)
variants predicted to be compound heterozygous or homo-
zygous. We then prioritized variants in genes coding for
proteins with known or predicted mitochondrial localiza-
tion.14 This filtering strategy led to the identification of
recessive variants in COQ4, coding for a mitochondrial
protein involved in CoQ10 biosynthesis,
10 in all three
subjects. In S2, we used the SeqCap EZ Library (version
1.0; Roche NimbleGen). Details on the bioinformatics
pipeline and variant filtering have been reported re-
cently.15 Sequencing statistics are provided in Table S1.
We identified COQ4 mutations (RefSeq accession num-
ber NM_016035.3) in four individuals (Figure 1). In S1,
we identified a homozygous missense variant, c.433C>G
(p.Arg145Gly). Both parents and a healthy sister are het-
erozygous carriers, and a healthy brother has two reference
alleles. No material was available from the deceased sister.
S2 was found to be compound heterozygous for a nonsense
variant on the paternal allele and a missense variant on
the maternal allele: c.[421C>T];[718C>T], p.[Arg141*];
[Arg240Cys]. S4 was found to be compound heterozygous
for a missense mutation and an exon 5 in-frame deletion:
c.[155T>C];[521_523delCCA], p.[Leu52Ser];[Thr174del].
Both variants were also confirmed in the DNA of S3,
whereas the parents are heterozygous for only one variant
each (the father carries the missense mutation, and the
mother carries the deletion). In S5, we identified a homo-
zygous mutation, c.190C>T (p.Pro64Ser). Both parents
are heterozygous for this mutation.
None of the identified variants are present in our exome
database, which contains 4,500 samples, or in public SNP
databases, including dbSNP, the NHLBI Exome Sequencing
Project Exome Variant Server, and the Exome Aggregation
Consortium (ExAC) Browser. The only exception is the
c.718C>T variant (rs143441644), which is reported to
have an extremely low frequency (MAF ¼ 0.00023; 28/
12,0330 alleles) in the ExAC Browser. Moreover, all
missense changes are predicted to be deleterious by several
bioinformatics tools (Table S2).
Because of the identified genetic defects, we tested
CoQ10 levels in available specimens from the subjects. In
a muscle biopsy from S1, we detected a clear reduction of
CoQ10 (32.9 nmol CoQ10/g protein; n.v. ¼ 101–183;
1.16 nmol CoQ10/CS; n.v. ¼ 1.75–3.46). In fibroblasts
from S1, the levels of CoQ10 were also lower than CoQ10
levels in neonatal control fibroblasts (54% of control
mean). In frozen muscle from S3, CoQ10 was reduced
(13.5 nmol CoQ10/g protein; n.v. ¼ 160–1,200; 0.3 nmol
CoQ10/CS; n.v. ¼ 2.7–7); in muscle from S4, CoQ10 was
profoundly reduced (25.7 nmol CoQ10/g protein; n.v. ¼
160–1,200; 0.1 nmol CoQ10/CS; n.v. ¼ 2.7–7), whereas in
S5 muscle, the amount of CoQ10 was slightly decreased5, 2015
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Figure 2. Biochemical Studies in COQ4
Mutant Muscle and Fibroblasts
(A) CoQ10 in muscle from affected subjects
S1 and S3–S5 is reported as a percentage of
the mean of control values (the analyses
were performed in different laboratories,
and the reference values are diverse; see
text). Data are reported after normaliza-
tion to protein content or CS activity.
(B) Maximal respiration rate (MRR)
measured in fibroblasts from subjects S1,
S4, and S5; MRR values are expressed as
percentages of MRR values obtained in
control fibroblasts. The graphs represent
the mean values from two independent
experiments, each with six to eight repli-
cates. Error bars represent the SD.
(C) Immunoblot analysis of COQ4 in fi-
broblasts from subjects S1, S4, and S5 and
control individuals (Ct). Arrowheads indi-
cate the band corresponding to COQ4.
An antibody against tubulin was used as
a loading control.(88.9 mg CoQ10/g protein; n.v. ¼ 101–183; 1.70 mg nmol
CoQ10/CS; n.v. ¼ 1.75–3.46) (Figure 2A). No residual sam-
ple from the muscle biopsy of S2 was available. Together,
these findings are consistent with a deleterious role of
the mutations identified in COQ4.
By Seahorse micro-oxygraphy,16 we detected that
maximal respiratory rates were lower in S1, S4, and S5 fi-
broblasts than in control cells (Figure 2B). Moreover, a
drastic decrease in the amount of COQ4 was detected by
immunoblot analysis in S1, S4, and S5 fibroblasts (Fig-
ure 2C), confirming that the identified COQ4 nucleotide
variants are deleterious.
The Saccharomyces cerevisiae ortholog of human COQ4 is
yCOQ4; yCOQ4-null strains have been reported to be effec-
tively complemented by human COQ4.10 In order to func-
tionally test the effect of all the mutations found in our
cohort, we transformed a COQ4-null strain (Dcoq4) by in-
serting the following hCOQ4 variants into the multicopy
pYES2.1 vector: pYES:hCOQ4WT (human wild-type [WT]),
pYES2.1 (empty vector), pYES:yCOQ4WT (positive con-
trol), pYES:hcoq4p.Arg145Gly (mutation c.433C>G), pYES:
hcoq4p.Arg141* (c.421C>T), pYES:hcoq4p.Arg240Cys (c.718C
>T), pYES:hcoq4p.Leu52Ser (c.155T>C), pYES:hcoq4p.Thr174del
(c.521_523delCCA), and pYES:hcoq4p.Pro64Ser (c.190C>T).
In addition, to replicate the compound-heterozygous con-
dition found in probands of families 2 and 3, we trans-
formed the Dcoq4 strain via a pYES construct harboring
both the c.155T>C and the c.521_523delCCA mutations
(pYES:hcoq4p.Leu52Ser/p.Thr174del) and a pYES construct ex-
pressing the c.421C>T and c.718C>T mutations (pYES:
hcoq4p.Arg141*/p.Arg240Cys). A WT strain transformed with
the pYES2.1 empty vector was also included as an addi-
tional control. In order to reveal a possible respiratory
defect, we compared the growth of our transformant
strains cultured in either glucose (a fermentable carbon
source) or glycerol (a non-fermentable carbon source) afterThe Americinducing gene expression with galactose for 4 hr. Notably,
whereas the growth of the pYES2.1:hCOQ4WT transformant
strain was comparable to that of the pYES2.1:yCOQ4WT
transformant strain, the strains transformed with the
hCOQ4 mutant vectors grew as slowly as that transformed
with pYES2.1 (Figure 3A). This result clearly indicates that
each mutation reported in our probands leads to a virtually
complete loss of function of the corresponding protein,
COQ4. Next, we found that the CoQ6 content in one
Dcoq4 mutant strain, hcoq4p.Arg145Gly, was markedly dec-
reased, whereas Dcoq4 strains transformed with either
pYES2.1:yCOQ4 or pYES2.1:hCOQ4hadCoQ6 levels similar
to those in the WT strain (Figure 3B). This result indicates
that mutant hcoq4p.Arg145Gly impairs CoQ biosynthesis.
Primary CoQ10 deficiency, caused by genetic defects in
CoQ10 biosynthesis, is a clinically heterogeneous condition
associated with a spectrum of different phenotypes, in-
cluding encephalomyopathic forms with seizures and/or
ataxia,17–19 multisystem infantile forms with encephalo-
myopathy and renal failure,20 nephrotic syndrome with
sensorineural deafness,21,22 adult Leigh syndrome,23 and
isolated myopathic forms.24 Mutations in seven genes
encoding proteins involved in CoQ10 biosynthesis have
been reported in single families or in a few singleton
cases;25 the genetic defect has not been determined in
most of the cases of CoQ10 deficiency, and only a few
data are available regarding specific genotype-phenotype
correlations. Secondary CoQ10 deficiency has been reported
in association with glutaric aciduria type IIC (MIM
231680), caused by mutations in ETFDH (MIM 231675; en-
coding electron-transfer dehydrogenase); ataxia-oculomo-
tor apraxia syndrome (MIM 208920), caused by mutations
in APTX (MIM 606350; encoding aprataxin); a cardio-
facio-cutaneous syndrome caused by a mutation in BRAF
(MIM 115150; encoding serine/threonine-protein kinase
B-Raf)26; and glucose transporter GLUT1 deficiency.27an Journal of Human Genetics 96, 309–317, February 5, 2015 313
Figure 3. Yeast Studies
(A) Glycerol (YPG) growth of transformed DCOQ4 yeast with the different mutated versions of human COQ4 (pYES2.1, empty vector;
hCOQ4, pYES:hCOQ4WT; yCOQ4, pYES:yCOQ4WT; c.433C>G, pYES:hcoq4p.Arg145Gly; c.421C>T, pYES:hcoq4p.Arg141*; c.718C>T, pYES:
hcoq4p.Arg240Cys; c.155T>C, pYES:hcoq4p.Leu52Ser; c.521_523delCCA, pYES:hcoq4p.Thr174del; c.190C>T, pYES:hcoq4p.Pro64Ser; c.155T>C
and c.521_523delCCA, pYES:hcoq4p.Leu52Ser/p.Thr174del; and c.421C>T and c.718C>T, pYES:hcoq4p.Arg141*/p.Arg240Cys). WT indicates the
wild-type yeast transformed with the YES2.1 empty vector. Cells were grown in selective medium for 16 hr, induced in galactose for
4 hr, and inoculated in YPG at 0.1 U of optical density (OD) at 600 nm. Growth at 30C was monitored over 5 days by measurement
of OD cultures at 600 nm.
(B) Yeast mitochondrial CoQ6 levels. Purified mitochondria lipid extraction and high-performance-liquid-chromatography quantifica-
tion of CoQ6 was performed in the DCOQ4 strain transformed with the empty vector (pYES2.1), WT yeast (yCOQ4), or human (hCOQ4)
or hcoq4p.Arg145Gly (c.433C>G) COQ4 genes. AWTstrain transformed with the empty vector was included as a positive control. Error bars
represent the SD.Interestingly, although the mechanisms linking these het-
erogeneous genetic conditions to a decrease in CoQ10
remain obscure, most of these individuals benefitted from
CoQ10 supplementation.
28,29
We found six COQ4 mutations in five affected sub-
jects from four unrelated families. All these individuals car-
ried homozygous or compound-heterozygous mutations,
clearly indicating that the resulting disease is an auto-
somal-recessive trait. Two alleles carried nonsense muta-
tions, which are both transmitted by descent in com-
bination with missense COQ4 mutations to different
individuals (S2 and sisters S3 and S4) and are predicted to
lead to a truncated and aberrant COQ4. Given that the het-
erozygous parents carrying the nonsense mutations are
alive and well, it is unlikely that COQ4 haploinsufficiency
is pathogenic, even though a previous study reported on a
boy carrying a de novo heterozygous deletion, including
COQ4, in chromosomal region 9q34.30 Because the biosyn-
thetic pathway of CoQ is conserved throughout evolution
from human to Saccharomyces cerevisiae, we modeled in
yeast the mutations found in our subjects. Using this sys-
tem, we demonstrated that each mutation, or the allelic
combinations found in S2 and siblings S3 and S4, was asso-
ciated with a severe defect of oxidative growth. In parallel,
we also showed that COQ4was strongly reduced inmutant
fibroblast cell lines from S1, S4, and S5. In the skeletal mus-
cle of S1 and S3–S5, the CoQ10 content was reduced as well.
Taken together, these results demonstrate the pathogenic
role of the COQ4 mutations found in our cohort.
In keeping with the essential role of COQ4, four of our
five subjects had a prenatal or perinatal onset with a fatal
outcome in the first days of life. S1 and S2 presented314 The American Journal of Human Genetics 96, 309–317, Februarywith severe hypotonia, bradycardia, and respiratory in-
sufficiency at birth; in S2, hypertrophic cardiomyopathy
had been evident since fetal development. A markedly
different, albeit equally severe, clinical presentation domi-
nated by premature delivery, antenatal cerebellar hypopla-
sia, neonatal respiratory-distress syndrome, and epileptic
encephalopathy characterized sisters S3 and S4. Rapidly
progressive, severe lactic acidosis was a common feature
in all four affected newborn subjects and is likely to have
determined their fatal outcome. Involvement of the heart
has been very rarely documented in CoQ10-deficient sub-
jects, often as part of multisystem phenotypes, where car-
diomyopathy develops later than brain, muscle, or kidney
impairment.20 For instance, a homozygous nonsense mu-
tation in COQ9 was described in a baby who presented
with neonatal lactic acidosis and later developed hypertro-
phic cardiomyopathy as part of a multisystem disease
including intractable seizures, global developmental delay,
and renal tubular dysfunction.9 In spite of his early onset,
the clinical course of S5 was slowly progressive and domi-
nated by neurological deterioration with hardly any
involvement of other organs, including the heart and
kidneys.
Although the link between specific genetic defects and
phenotypes is often unclear inmitochondrial disorders, or-
gans with the highest energy requirements, such as the
heart, kidneys, and brain, have the highest CoQ10 concen-
trations31 and are the most frequently affected by CoQ10
deficiency. The level of expression of COQ genes in
different cells seems to correlate poorly with the primarily
affected tissue or organ; for instance, COQ2, mutations of
which typically cause renal impairment, has expression5, 2015
levels that are relatively higher in skeletal muscle and the
heart than in other organs,32 whereas COQ4, mutated in
our subjects with cardiac or brain failure, is ubiquitously
expressed and has relatively higher levels in the liver,
lungs, and pancreas.
Because cardiomyocytes have a remarkably high energy
requirement, and cardiomyopathy is quite common in in-
dividuals with various inherited mitochondrial disorders,
the cardiac involvement in subjects with mutations in
COQ genes can be overlooked. Indeed, the crucial role of
CoQ10 in cardiomyocyte function has been recognized
for a very long time; for instance, myocardial biopsies
from individuals with congestive heart failure33 or cardio-
myopathy34,35 show low CoQ10 levels, which correlate
with the severity of heart damage.36 Moreover, statins,
cholesterol-lowering drugs that inhibit HMG-CoA reduc-
tase (the key enzyme common to the biosynthesis of
both cholesterol and CoQ10) can cause CoQ10 deficiency,
ultimately leading to cardiomyopathy;37 interestingly,
this harmful side effect can be overcome by oral CoQ10
supplementation.38 Moreover, long-term CoQ10 treat-
ment of individuals with chronic heart failure is safe,
improves symptoms, and reduces major adverse car-
diovascular events.39 These observations all converge
on a strict association between CoQ10 deficiency and
cardiomyopathy.
Notably, S3–S5 showed no sign of heart involvement,
whereas the clinical phenotype was dominated by enceph-
alopathy with seizures and a more progressive, but mainly
neurological, syndrome is the clinical hallmark of S5, indi-
cating the heterogeneity of the clinical presentations asso-
ciated with COQ4 defects. The variable specificity of organ
failure (e.g., heart versus brain) in the neonatal cases of our
cohort could be due to the fulminant course of the disease,
which prevented the deployment of multisystem involve-
ment. In support of this view, although cardiomyopathy
dominated the clinical picture, the presence of severe hy-
potonia and hyporeflexia suggests concomitant involve-
ment of the nervous system in S1 and S2 as well. Clinical
heterogeneity was accompanied by an equally striking
variability of the biochemical findings, which ranged
from multiple (S1 and S5) to isolated (S2 and S3) ETC de-
fects in muscle and fibroblasts to hardly any detectable
defect at all (S4). This biochemical diversity could be due
to differences in individual adaptive responses to reduced
CoQ10 availability or could reflect the striking tissue spec-
ificity observed in the clinical presentations, but at the
moment, a mechanistic explanation for these observations
is lacking. Poor correlation with the clinical and biochem-
ical phenotypes has also been reported for other genes
related to CoQ10 biosynthesis. For instance, mutations in
COQ2, the first mutated gene identified in affected individ-
uals with primary CoQ10 deficiency, have been associated
with a wide range of clinical presentations, often including
nephrotic syndrome but also including fatal neonatal mul-
tisystemic disorder, Leigh syndrome, myoclonic epilepsy,
hypertrophic cardiomyopathy, deafness, and adult-onsetThe Americmultisystem atrophy.25,40 In any case, the identification
of COQ4mutations in subjects with such a wide spectrum
of clinical and biochemical abnormalities is a further indi-
cation of the advantage of unbiased screening such asWES
for the identification of genes newly associated with mito-
chondrial disorders.
Unfortunately, the fulminant fatal outcome in S1–S4
was so rapid that it prevented both the diagnosis of
CoQ10 deficiency and the start of CoQ10 supplementation.
Prompt diagnosis is a main challenge for syndromes of pri-
mary CoQ10 deficiency but is very important given that
co-factor deficiencies are virtually the only group of mito-
chondrial disorders for which beneficial pharmacological
treatment is currently available. Treatment of the long-sur-
viving subject, S5, has now started and will hopefully pro-
vide some useful indication of its efficacy in the near
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